Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OST31-164 Maintenance in Recurrent Resected Osteosarcoma
NCT04974008Phase 2Active, not recruiting
- Sponsor
- Emerald Clinical
- Start
- Oct 2021
- Primary completion
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of daznelimgene lisbac in osteosarcoma (OS), sponsored by Emerald Clinical. Started Oct 2021; status: active, not recruiting.
02
Drugs
daznelimgene lisbac
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT04974008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04974008.